Loading...
XNASARAY
Market cap231mUSD
Jan 16, Last price  
2.30USD
1D
0.00%
1Q
21.69%
Jan 2017
-50.00%
IPO
-92.14%
Name

Accuray Inc

Chart & Performance

D1W1MN
XNAS:ARAY chart
P/E
—
P/S
0.52
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
2.36%
Rev. gr., 5y
1.29%
Revenues
447m
-0.24%
22,377,00052,897,000140,452,000210,381,000233,598,000221,625,000222,284,000409,223,000315,974,000369,419,000379,801,000398,800,000383,414,000404,897,000418,785,000382,928,000396,289,000429,909,000447,605,000446,551,000
Net income
-16m
L+67.51%
-25,189,000-33,694,000-5,616,0005,383,000609,0002,841,000-26,682,000-72,042,000-103,219,000-35,448,000-40,209,000-25,504,000-29,579,000-23,899,000-16,430,0003,827,000-6,311,000-5,347,000-9,280,000-15,545,000
CFO
-12m
L
18,015,00025,505,00011,597,000-17,989,000-8,046,000-5,073,00012,403,000-38,279,000-66,177,000346,000-16,733,00033,538,000-380,00018,331,000-29,641,000-1,469,00038,512,000-2,400,00015,539,000-11,904,000
Earnings
Jan 29, 2025

Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas, and kidney. The company also provides the TomoTherapy System, including the Radixact System, which consists of an integrated radiation therapy system designed for the treatment of a range of cancer types. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.
URL
https://www.accuray.com/
IPO date
Feb 08, 2007
Employees
1,044
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
446,551
-0.24%
447,605
4.12%
429,909
8.48%
Cost of revenue
446,047
445,223
421,761
Unusual Expense (Income)
NOPBT
504
2,382
8,148
NOPBT Margin
0.11%
0.53%
1.90%
Operating Taxes
3,725
2,492
3,345
Tax Rate
739.09%
104.62%
41.05%
NOPAT
(3,221)
(110)
4,803
Net income
(15,545)
67.51%
(9,280)
73.56%
(5,347)
-15.27%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,247
2,200
3,631
BB yield
-1.26%
-0.60%
-2.01%
Debt
Debt current
20,192
14,023
17,130
Long-term debt
235,364
222,917
229,862
Deferred revenue
24,114
27,079
3,748
Other long-term liabilities
7,389
4,675
10,453
Net debt
177,160
132,410
144,376
Cash flow
Cash from operating activities
(11,904)
15,539
(2,400)
CAPEX
(3,601)
(12,681)
(4,717)
Cash from investing activities
(3,601)
(12,681)
(4,717)
Cash from financing activities
(3,951)
(2,112)
(15,369)
FCF
(45,380)
(2,589)
(4,247)
Balance
Cash
68,570
89,402
88,737
Long term investments
9,826
15,128
13,879
Excess cash
56,068
82,150
81,121
Stockholders' equity
(521,803)
(501,617)
(490,022)
Invested Capital
815,355
775,440
762,921
ROIC
0.62%
ROCE
0.17%
0.87%
2.99%
EV
Common stock shares outstanding
98,272
94,884
92,095
Price
1.82
-52.97%
3.87
97.45%
1.96
-56.64%
Market cap
178,855
-51.29%
367,201
103.43%
180,506
-56.61%
EV
356,015
499,611
324,882
EBITDA
6,409
6,909
13,661
EV/EBITDA
55.55
72.31
23.78
Interest
11,624
10,632
8,129
Interest/NOPBT
2,306.35%
446.35%
99.77%